CD79A and breast carcinoma: In order to investigate whether IFN-γ enhanced BBB passage of the MDA-MB-231 breast cancer cells we used neutralizing antibodies to the IFN-γ molecule (anti-hIFN-γ-IgA), and blocked the INF-γ receptor IFNGR1 by using a monoclonal antibody (human IFNGR1/CD119).